The report, Resilience in volatility: Modernizing the supply chain, highlights three areas that Fortune 500 and mid-size companies need to address to implement technology such as machine learning, cloud computing and risk management tools to improve production and delivery.
The report, Resilience in volatility: Modernizing the supply chain, highlights three areas that Fortune 500 and mid-size companies need to address to implement technology such as machine learning, cloud computing and risk management tools to improve production and delivery.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Value-based contracts covering the reimbursement of drugs and medical devices are slowly gaining acceptance. A panel at the MedCity News INVEST conference discussed the challenges and opportunities for these contracts, which aim to improve patient outcomes and control the cost of care.
A new partnership between Amazon and First Databank will let users ask Alexa for basic information about the most commonly prescribed drugs.
Proteus, which makes tiny sensors that can track medication adherence, will no longer develop the technology in behavioral health medications for Otsuka Pharmaceutical. Instead, the startup is shifting its focus to oncology and infectious diseases, where it hopes its tech will have better traction.
Through the 340B program, the government is able to negotiate drug pricing for patients seeking care in certain covered entities and the savings from this program should be passed on to consumers.
The pharmaceutical industry has introduced extraordinary health-care advances but if we don’t get a handle on the perverse incentives operating throughout the system, we may be pricing ourselves and our economy into oblivion.
The biotech century has arrived, and it's consequently now more important than ever for us to highlight our coverage of biopharma.
The report, by PitchBook, shows figures consistent with a similar report earlier this month by Silicon Valley Bank, which forecast more M&A deals this year.
The acquisition brings together two of the largest drugmakers in the country, both of which are major players in biopharma, particularly oncology.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Although blockchain faces regulatory hurdles and skepticism, its potential as a shared, yet secure ledger system to improve the pharmaceutical supply chain integrity and clinical trials is making it attractive for experimentation and investment by drugmakers.
The company, which is a distributor of pharmaceuticals and a division of AmerisourceBergen, offers two inventory management systems: CubixxMD and PODIS Plus.
The company's life sciences track-and-trace network reaches drugmakers, pharmacies and others, with a customer base of more than 930 companies.
By complementing life science marketing strategies with Facebook Live, companies will be able to connect with and engage more people in a more familiar and direct manner, which will drive digital word-of-mouth.
Doctors in the Northwest are once again rethinking aid-in-dying medications because they’re taking too long to work.
